Registration Dossier

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in chemico
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
The experimental start date was 03 Dec 2018, and the experimental completion date was 11 Dec 2018.
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2019
Report date:
2019

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
GLP compliance:
yes
Type of study:
direct peptide reactivity assay (DPRA)

Test material

1
Chemical structure
Reference substance name:
cis-N-methyl-N-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclobutane-1,3-diamine phosphate (1:1)
EC Number:
951-920-2
Molecular formula:
C11H15N5* H3PO4
IUPAC Name:
cis-N-methyl-N-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclobutane-1,3-diamine phosphate (1:1)

Results and discussion

In vitro / in chemico

Resultsopen allclose all
Run / experiment:
other: SPCC depletion
Parameter:
other: Cysteine 1:10 / Lysine 1:50
Value:
1.7
Positive controls validity:
valid
Remarks on result:
not determinable
Remarks:
Negative: No or minimal reactivity
Run / experiment:
other: SPCL depletion
Parameter:
other: Cysteine 1:10 / Lysine 1:50
Value:
0.6
Positive controls validity:
valid
Remarks on result:
not determinable
Remarks:
Negative: No or minimal reactivity

Applicant's summary and conclusion

Interpretation of results:
study cannot be used for classification
Conclusions:
In conclusion, since all acceptability criteria were met this DPRA is considered to be valid.
PF-03817968-09 was negative in the DPRA and was classified in the “no or minimal reactivity class” when using the Cysteine 1:10 / Lysine 1:50 prediction model. However, since the DPRA study was performed using a test item stock solution with a concentration of 25 mM instead of the required 100 mM, no firm conclusion on the lack of reactivity can be drawn from this negative result.
Executive summary:

The objective of this study was to determine the reactivity ofPF-03817968-09 towards model synthetic peptides containing either cysteine (SPCC) or lysine (SPCL). After incubation of the test item with either SPCC or SPCL, the relative peptide concentration was determined by High-Performance Liquid Chromatography (HPLC) with gradient elution and spectrophotometric detection at 220nmand 258nm.SPCC and SPCL Percent Depletion Values were calculated and used in a prediction model which allows assigning the test item to one of four reactivity classes used to support the discrimination between sensitizers and nonsensitizers. The study procedures described in this report were based on the most recent OECD guideline. No appropriate solvent was found to dissolve the test item at a concentration of 100 mM. Milli-Q water(MQ)was found to be an appropriate solvent to dissolve the test item at a concentration of 25 mM and was, after consultation with the Sponsor, used in this Direct Peptide Reactivity Assay (DPRA) study.

The validation parameters, i.e. calibration curve, mean concentration of Reference Control (RC) samples A, C and CMQ, the CV for RC samples B and C, the mean percent peptide depletion values for the positive control with its standard deviation value and the standard deviation value of the peptide depletion for the test item, were all within the acceptability criteria for the DPRA. Upon preparation as well as after incubation of the SPCC and SPCL test item samples, no precipitate or phase separation was observed in any of the samples. An overview of the individual results of the cysteine and lysine reactivity assays as well as the mean of the SPCC and SPCL depletion are presented in the table below. In the cysteine reactivity assay the test item showed 1.7% SPCC depletion while in the lysine reactivity assay the test item showed 0.6% SPCL depletion. The mean of the SPCC and SPCL depletion was 1.1% and as a result the test item was considered to be negative in the DPRA and classified in the “no or minimal reactivity class” when using the Cysteine 1:10 / Lysine 1:50 prediction model.

In conclusion, since all acceptability criteria were met this DPRA is considered to be valid. PF-03817968-09 was negative in the DPRA and was classified in the “no or minimal reactivity class” when using the Cysteine 1:10 / Lysine 1:50 prediction model. However, since the DPRA study was performed using a test item stock solution with a concentration of 25 mM instead of the required 100 mM, no firm conclusion on the lack of reactivity can be drawn from this negative result.